Long Ideas - Merck & Co. (NYSE:MRK) reported better than expected earnings Friday morning, with EPS of $0.95 vs. the Street Consensus of $0.93. While 3Q total revenues … Continue Reading
Read NowLong Ideas - One of the most controversial companies in the biotechnology sector today is Dendreon (NASDAQ:DNDN). To some, the company represents the worst of Wall Street, an … Continue Reading
Read NowLong Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) trounced 3Q 2012 earnings expectations, with reported revenues of $140.3M and adjusted EPS of $0.97 for the period. This compares to Wall Street … Continue Reading
Read NowLong Ideas - Amarin Corp. (NASDAQ:AMRN) got a bump in the pre-market Tuesday after announcing that two more patents have been added to Vascepa’s Intellectual Property, protecting the … Continue Reading
Read NowMost Popular - The Health Care Select Sector SPDR (XLV), the exchange traded fund (ETF) that tracks the Health Care Select Sector Index, gained $0.03 or 0.07% on … Continue Reading
Read NowMost Popular - PropThink published its latest report on Keryx Biopharmaceuticals last week, and on Monday we followed up with some technical discussion. We also included QCOR in … Continue Reading
Read NowMost Popular - Geron Corp (NASDAQ:GERN) may have finally found a buyer for its suspended stem cell program. The company has been searching since November of 2011 when … Continue Reading
Read Now